Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), bought 15,000 shares at $3.43 ($51K) on 2021-08-30, disclosed to the SEC on 2021-08-31.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Clearly above the average filing.
| Filing → |
| RSLS | SELL | 2023-07-19 | $156 | — | Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |